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Oral Presentations S187intraperitoneal administration of 2 mg PTN or saline  7 days, fol-
lowed by analysis of BM stem and progenitor cell content. Saline-
treated mice demonstrated a significant reduction in total BM cells,
BM c-kit+sca-1+lin- (KSL) cells, colony forming cells (CFCs) and
long term culture-initiating cells (LTC-ICs) compared to non-irra-
diated mice. Irradiated, PTN-treated mice demonstrated a 2.3-fold
increase in total BM cells (p5 0.03), a 5.6-fold increase in BM KSL
stem/progenitor cells (p5 0.04), a 2.9-fold increase in BM CFCs
(p5 0.004) and an 11-fold increase in LTC-ICs (p5 0.03) com-
pared to irradiated, saline-treated mice. Moreover, competitive
repopulating assays demonstrated that BM from irradiated,
PTN-treated mice contained 5-fold increased competitive repopu-
lating units (CRUs) compared to irradiated, saline-treated mice
(p5 0.04). Taken together, these data demonstrate that the admin-
istration of PTN induces BM HSC and progenitor cell regenera-
tion in vivo following injury. To determine whether PTN acted
directly on BM HSCs to induce their proliferation and expansion
in vivo, mice ingested BrDU  7 days and compared BrDU incor-
poration in BM KSL cells in saline-treated versus PTN-treated
mice. PTN-treated mice demonstrated a significant increase in
BrDU+ BM KSL cells compared to saline-treated controls
(p5 0.04). PTN is a novel, secreted growth factor for BM HSCs
and induces their regeneration in vivo while preserving their repo-
pulating capacity. PTN has therapeutic potential as a growth factor
to accelerate hematopoietic reconstitution in vivo in patients un-
dergoing myelosuppressive radiotherapy or chemotherapy.86
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Murine embryonic stem cells (mESCs) can grow indefinitely
in vitro, and yet retain the potential to differentiate into all three
primitive germ layers. They hold significant promise within the
field of regenerative medicine, particularly through the production
of patient specific induced pluripotent cells (iPS), which mimic the
properties of embryonic stem cells. The ability of mESCs to main-
tain their pluripotency is regulated by a number of transcription
factors, including Sall4, the causative gene in Duane-Radial Ray
syndrome (DRSS), consisting of radial, cardiac, and eye abnormal-
ities. Sall4 is critical for maintaining mESCs in a pluripotent state,
and interestingly exists as two isoforms (Sall4a, the long isoform
and Sall4b, the short isoform); Sall4b has been implicated as an on-
cogene in acute myelogenous leukemia (AML). Using genome
wide location anaylsis, we have been able to show that both iso-
forms of Sall4 exist in mESCs and bind to overlapping but not
identical target genes. In fact, Sall4b (the short isoform) binds to
most pluripotency targets, whereas Sall4a binds predominantly to
differentiation genes. Using RNAi technology to generate mESCs
containing only one of the two isoforms we demonstrate that
Sall4b but not Sall4a is required for maintaining mESCs in a plu-
ripotent state. Lastly, proteomics reveals that Sall4a and Sall4b may
have different protein:protein interaction partners which affects
their ability to regulate pluripotency targets. Taken together, these
data indicate that differences in splice variants at a single locus can
play key roles in regulating the pluripotent states. Further studies
need to be performed to understand how these differences may
translate into the unique roles these splice isoforms play in human
diseases.87
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Research in the field of allogeneic hematopoietic cell transplan-
tation (allo-HCT) revealed hidden consequences of the co-exis-
tence of two genetically distinct populations in the transplant
recipient. First, epithelial cells with donor-derived genotype
emerge and second, epithelial tissues of the host acquire genomic
alterations. We asked whether horizontal transfer of donor-DNA
to host epithelium is operating in (and linking) both phenomena.
176 buccal samples were obtained from 71 allo-transplanted pa-
tients and analyzed with microsatellite markers for the presence
of donor-DNA and microsatellite instability. The presence of
graft-derived hematopoietic cells in the samples was excluded by
immunocytochemistry. The results were associated with clinical
data. Genomic instability induction and DNA transfer in epithelial
cells by allogeneic lymphocytes was assessed in vitro. We found
a high contribution of donor-DNA (mean 26.6%) in buccal sam-
ples in 61 out of 68 evaluable patients. In addition, 32% of the sam-
ples were positive for microsatellite instability. The extent of
donor-DNA was significantly correlated with the occurrence of
genomic alterations (p\0.05). The age of the patient and a female-
to-male transplantation were significantly correlated with
microsatellite instability. There was a trend for increasing risk of
microsatellite instability for patients who experienced severe
graft-versus-host disease. During follow up secondary malignancy
was diagnosed in 5 patients (14%) who exhibited microsatellite in-
stability but only in 1 (3%) with no instability. In an in vitro model,
we demonstrated that apoptotic lymphocytes may not only induce
genomic alterations but also transfer DNA in co-cultured epithelial
cells, resulting in the creation of hybrid chromosomes. Our results
indicate that continuous charge of the transplant recipient with ap-
optotic donor-DNA and its illegitimate integration into host epi-
thelium may come in light as epithelial cells with donor-derived
genome or instability events and may provide a new model for elu-
cidating protean clinical manifestations after allo-HCT, such as
secondary malignancy.88
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We previously developed methods to purify human hematopoi-
etic progenitors based on their high expression of aldehyde dehydro-
genase (ALDHbr cells), which enrich both short- and long-term
SCID-repopulating cells. One clinical trial now suggests that aug-
menting a conventional cord blood transplant (CBT) with ALDHbr
cells accelerates both neutrophil and platelet engraftment. We now
describe two experimental models for this clinical regimen, per-
formed in different strains of NOD/SCID mice. Each study in-
cluded three cohorts: (1) mice transplanted with 4,000 purified
ALDHbr cells; (2) mice transplanted with total CB at a dose that
contained 4,000 ALDHbr cells; and, (3) mice that first received the
same dose of unmanipulated CB and, after 4 hours, the ALDHbr
cells.
In NOD/SCID-IL2Rgnull (NSg) mice, human ALDHbr cells ex-
hibited strong chimerism including bone marrow CD33+CD15+
neutrophils and circulating CD41+ platelets, by 4 weeks post-trans-
plant. Unmanipulated CB also engrafted the bone marrow of NSg
mice, but .95% of the cells were CD3+ T cells. Myeloid engraft-
ment was low to undetectable. When CB grafts were augmented
with ALDHbr cells, bone marrow chimerism increased .2-fold rel-
ative to mice that received CB alone (P5 0.006). However, like
mice that received CB alone, the human cells within the bone mar-
row were mainly T cells; myeloid engraftment remained low to
undetectable.
S188 Oral PresentationsIn NOD/SCID-b2-microglobulinnull (NSb) mice, human
ALDHbr cells also established short-term human myeloid develop-
ment, including CD41+ platelets. In contrast, engraftment by total
CB was very low. However, human hematopoietic chimerism in-
creased .10-fold when total CB was augmented 4 hours later with
ALDHbr progenitors. By using HLA-matched (6/6), but sex-
mismatched CB, continuing studies will examine the relative contri-
butions of the ALDHbr cells and the total CB.
Unmanipulated CB did not yield efficient short-term myeloid en-
graftment in either NOD/SCID strain. In contrast, ALDHbr pro-
genitors established human myeloid development in both strains.
Furthermore, ALDHbr cells altered the outcome of CB transplants
in two distinct ways. In NSg mice, the ALDHbr progenitors facili-
tated either the engraftment or the proliferation of T cells. In NSb
mice, ALDHbr progenitors appeared to directly augment short-
term myeloid engraftment by total CB. Importantly, the latter stud-
ies reflect the clinical experience of early CBT trials that use this
strategy.
Hematopoietic chimerism in NSg and NSbmice
NOD/SCID Chimerism,
strain Graft %huCD4516 SD CompositionNSg ALDHbr 126 4.9% (n5 5) Myeloid and B cells
NSg CB 7.46 4.7% (n5 8) T cells
NSg CB 1ALDHbr 18.96 9.3% (n5 10) T cells
NSb ALDHbr 5.66 4.7% (n5 5) Myeloid and B cells
NSb CB 0.326 0.19% (n5 4) \detection limit
NSb CB 1ALDHbr 4.36 1.9% (n5 5) Myeloid and B cellsFor each mouse strain, the level of human hematopoietic chimerism
achieved within the bone marrow is provided for each cohort. The gen-
eral composition of the human progeny within the bone marrow is also
given.SUPPORTIVE CARE
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Background: IFI are significant causes of morbidity and death af-
ter HCT. Optimal antifungal prophylaxis following HCT is un-
certain. The potential of oral voriconazole required prospective
randomized evaluation. Itraconazole oral solution is a mold-active
agent with evidence for efficacy and documented safety in HCT
patients.
Methods: Prospective, open-label, multicenter study for primary
IFI prophylaxis after allogeneic HCT. Patients .5 12 years
were randomized (stratified by conditioning regimen intensity
and donor type) to receive oral voriconazole or oral itraconazole
from the day of HCT for at least 100 and up to 180 days. Pri-
mary composite endpoint was success of prophylaxis at Day
180, i.e. patient survived without developing proven/probable
IFI or discontinuing prophylaxis for.14 days during the
first 100 days. The study was powered to demonstrate non-
inferiority at day 180. If non-inferiority was shown, superiority
was tested.Results: 234 patients were randomized and treated with vorico-
nazole and 255 with itraconazole; all received.1 dose of study
drug. Success of prophylaxis was significantly higher with vori-
conazole than with itraconazole at Days 100 (55% vs 41%; ad-
justed for conditioning regimen and relatedness of donor 95%
CI for difference: 6%, 24%; p5 0.0007) and 180 (49% vs
35%; adjusted 95% CI for difference: 7%, 24%; p5 0.0004).
Significantly more voriconazole than itraconazole (54% vs
40%; p5 0.0014) patients had sufficient days of prophylaxis
(median: 97 vs 68 days). IFI incidence was low in both arms
(voriconazole: 1.3%, itraconazole: 2.4%); no patients developed
IFI while receiving voriconazole, compared with 3 itraconazole
patients (p5 0.08). There was no difference in survival at Day
100 and 180 (94% and 85% in both arms at respective time-
points). 1-year survival was 75% and 69% in voriconazole
and itraconazole arms respectively (p5 0.1256 for the difference
in proportions). The most common treatment-related adverse
events for voriconazole and itraconazole, respectively, were
vomiting (4% vs 16%), nausea (8% vs 15%), diarrhea (4% vs
11%), hepatotoxicity/liver function test abnormalities (12% vs
5%) and visual impairment (6% vs 0%) (p\5 0.01 for all com-
parisons).
Conclusions: Success of prophylaxis was significantly higher with
voriconazole than itraconazole. Primary prophylaxis with voricona-
zole is an effective, safe option for preventing IFI after allogeneic
HCT.
IFIs during study
Treatment Body Site
EORTC criteria Emergent* Pathogen of IFI3 in Voriconazole arm
Proven No Candida krusei Blood
Proven No Candida parapsilosis Blood
Probable No Aspergillus fumigatus Lung6 in Itraconazole arm
Proven Yes Candida glabrata Blood
Proven No Aspergillus fumigatus Lung
Probable Yes Aspergillus sp Lung
Probable Yes Aspergillus sp Lung
Probable No Aspergillus fumigatus Lung
Probable No Aspergillus sp LungTreatment-emergent IFIs: Voriconazole 0%, Itraconazole 1.2% (p5 0.08 for
difference).
*Treatment-emergent IFIs: occurring any time while patient was on
study drug and for 7 days following treatment discontinuation.90
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Background: Although screening of patients’ vital organ function
is routinely performed prior to autologous or allogeneic hemato-
poietic stem cell transplantation (HSCT), the lowest acceptable
threshold for function is not well defined. As a consequence, pa-
tients with significant organ dysfunction are often excluded from
transplantation. In order to make transplantation an option for
the maximum number of patients, retrospective studies have
been conducted to determine the impact of organ dysfunction
on transplantation outcome. The implication of transplanting pa-
tients with coronary artery disease (CAD) is one such area for
which there is no published data.
